Key result
Transcatheter tricuspid valve interventions offer a promising, less invasive alternative to surgery for high-risk patients with severe tricuspid regurgitation, though randomized trials are still ongoing.
Why the study?
Surgical options are rarely offered to patients with tricuspid regurgitation due to high surgical risk and medical therapy plays a limited role, creating an increasing clinical need for transcatheter treatment options.
Transcatheter tricuspid valve interventions represent a promising, minimally invasive alternative for high-risk patients with severe tricuspid regurgitation, though further randomized trials are needed to establish their efficacy compared to medical therapy.
May address unmet needs in high-risk TR; leaves open long-term efficacy and safety from randomized trials.
Tricuspid regurgitation (TR) has a not negligible prevalence and its severity is correlated with poorer outcomes. However, surgical options are rarely offered to these patients because of their high surgical risk. Given that medical therapy plays a limited role in the management of these patients, there is an increasing clinical need for transcatheter treatment options. Although, transcatheter tricuspid valve interventions (TTVIs) are still at an early stage, emerging data suggests their clinical effectiveness and safety, with preliminary results highlighting the potential benefits of transcatheter treatments over medical therapy. In this review, we highlight the challenges and future directions of current and emerging technologies dedicated to the treatment of TR along with an analysis of the next steps required in future clinical trials and studies dedicated to the treatment of the forgotten valve.
No takes yet. Share an insight, caveat, or question.
Mangieri et al. (2020) conducted a review in Tricuspid Regurgitation. Transcatheter tricuspid valve interventions (TTVIs) vs. Medical therapy or surgery (conceptual) was evaluated. Transcatheter tricuspid valve interventions offer a promising, less invasive alternative to surgery for high-risk patients with severe tricuspid regurgitation, though randomized trials are still ongoing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: